Markus Haeberlein

Markus is an accomplished R&D executive with three decades of experience in Drug Discovery and Early Development spanning many disease areas. Most recently, Markus served as Senior Vice President and Head of Research at Alkermes. During his tenure he helped build a strong research engine focused on exceptional molecular design of small molecules and biologics. An example is the discovery of ALKS 2680 for narcolepsy, a potent agonist for the difficult-to-drug Orexin 2 Receptor.
Before Alkermes, Markus was Chief Scientific Officer at Proteostasis Therapeutics, a biotech focused on diseases caused by improper protein degradation, folding and trafficking. Prior to that, Markus spent 15 years at AstraZeneca and held roles of increasing scope and responsibility, including leading AstraZeneca’s Global Chemistry Network where he was responsible for the company’s global chemistry strategy and implementation. A key focus of his strategy was the Predictive Chemistry platform utilizing state-of-the-art computational chemistry methods to improve the design of drug molecules.
Markus holds a M.Sc. in Physical Chemistry, Biochemistry, Organic Chemistry and a Ph.D. in Physical Chemistry/Computational Chemistry from the Royal Institute of Technology, Sweden.